Leadership: Page 2


  • Nikki Jones Headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: HBA’s Nikki Jones

    As the Healthcare Businesswomen’s Association’s first chief people and DEI officer, Jones is poised to tackle pay gap inequity, systemic gender bias and leadership barriers impeding women of color.

    By Oct. 12, 2022
  • bad boss
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    Are you a bad boss?

    Pharma execs share their tips for being a better leader.

    By Oct. 7, 2022
  • Fiona Elwood B&W WoW header
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Janssen’s Fiona Elwood

    The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.

    By Oct. 5, 2022
  • hiring stock
    Image attribution tooltip
    Stock via Getty Images

    The 2 areas in life sciences most in need of talent

    The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

    By Oct. 4, 2022
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Q&A

    Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

    Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

    By Oct. 3, 2022
  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images

    How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

    Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

    By Sept. 30, 2022
  • Samantha Dale Strasser headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Pepper Bio’s Samantha Dale Strasser

    The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

    By Sept. 28, 2022
  • Katharine Knobil
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

    As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

    By Sept. 14, 2022
  • Bubble
    Image attribution tooltip
    Petrovich9 via Getty Images

    From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

    The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.

    By Sept. 12, 2022
  • Cindy Mesaros
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Foresite Capital’s Cindy Mesaros

    The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

    By Sept. 7, 2022
  • CFO
    Image attribution tooltip
    joel-t via Getty Images
    First 90 Days

    First 90 Days: Adaptive Biotech’s Tycho Peterson

    A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

    By Sept. 1, 2022
  • Kim Boericke headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Thread’s Kim Boericke

    Fresh off an eight-year tour of duty at ICON, the CRO industry veteran is stepping into a new role and a new title as chief delivery officer at Thread.

    By Aug. 31, 2022
  • inside cell
    Image attribution tooltip
    Stock via Getty Images
    Profile

    Leading the industry’s next potential game-changer in drug discovery

    Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

    By Alexandra Pecci • Aug. 29, 2022
  • Tram Tran Glympse Bio
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Glympse Bio’s Dr. Tram Tran

    How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

    By Aug. 24, 2022
  • A light blue puzzle depicting rows of workers has scattered pieces missing, showing a yellow background underneath.
    Image attribution tooltip
    iStock via Getty Images
    Making Moves

    Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

    How the latest personnel shifts are impacting each company and the industry at large. 

    By Aug. 24, 2022
  • Taren Grom, editor-in-chief emeritus, PharmaVoice
    Image attribution tooltip

    Permission granted by Taren Grom.

    PharmaVoice 100

    The story behind the PharmaVoice 100

    Taren Grom, our editor-in-chief emeritus, explains how the coveted PharmaVoice 100 awards got its start and what makes it stand out in the industry.

    By Aug. 23, 2022
  • Image attribution tooltip
    E+ via Getty Images

    As pharma M&A ramps up, U.S. execs are bullish on more deals

    What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

    By Aug. 11, 2022
  • Miruna Sasu COTA
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: COTA’s Miruna Sasu

    Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.

    By Aug. 10, 2022
  • CEO pay
    Image attribution tooltip
    Stock via Getty Images

    Are Big Pharma CEOs earning their pay?

    While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

    By Kelly Bilodeau • Aug. 8, 2022
  • A hand picks a blue figurine out of rows of similar wooden figurines.
    Image attribution tooltip
    Ivan Balvan via Getty Images
    Making Moves

    Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

    How these latest executive personnel changes are impacting the industry. 

    By Aug. 3, 2022
  • Heather Schwoebel head shot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Alloy Therapeutics’ Heather Schwoebel

    The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

    By Aug. 3, 2022
  • Artifical intelligence
    Image attribution tooltip
    Olemedia via Getty Images
    Q&A

    How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

    WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

    By Kim Ribbink • Aug. 1, 2022
  • A person points a pen at a computer with a green line graph. A blurred computer in the background shows other graphs.
    Image attribution tooltip
    iStock via Getty Images

    What’s next for Biogen? Here’s what executives are saying

    A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

    By July 27, 2022
  • Katie Williams head shot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Applied BioMath's Katie Williams

    The 2022 president of Women in Bio is equal parts math and gender parity evangelist. 

    By July 27, 2022
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola/Staff via Getty Images

    With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

    Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.

    By July 21, 2022